Human Immunodeficiency Virus (HIV) Therapeutics Market, Global Outlook and Forecast 2022-2028
This report contains market size and forecasts of Human Immunodeficiency Virus (HIV) Therapeutics in Global, including the following market information:
Global Human Immunodeficiency Virus (HIV) Therapeutics Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Human Immunodeficiency Virus (HIV) Therapeutics market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
NRTIs Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Human Immunodeficiency Virus (HIV) Therapeutics include ViiV Healthcare, Mylan, AbbVie, Merck & Co., Inc., Bristol-Myers Squibb Company, Boehringer Ingelheim GmbH, Genentech, Inc., Cipla, Inc. and Boehringer Ingelheim GmbH and etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Human Immunodeficiency Virus (HIV) Therapeutics companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Human Immunodeficiency Virus (HIV) Therapeutics Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Human Immunodeficiency Virus (HIV) Therapeutics Market Segment Percentages, by Type, 2021 (%)
Global Human Immunodeficiency Virus (HIV) Therapeutics Market Segment Percentages, by Application, 2021 (%)
Global Human Immunodeficiency Virus (HIV) Therapeutics Market Segment Percentages, By Region and Country, 2021 (%)
The report also provides analysis of leading market participants including:
Key companies Human Immunodeficiency Virus (HIV) Therapeutics revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Human Immunodeficiency Virus (HIV) Therapeutics revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Global Human Immunodeficiency Virus (HIV) Therapeutics Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Human Immunodeficiency Virus (HIV) Therapeutics market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
NRTIs Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Human Immunodeficiency Virus (HIV) Therapeutics include ViiV Healthcare, Mylan, AbbVie, Merck & Co., Inc., Bristol-Myers Squibb Company, Boehringer Ingelheim GmbH, Genentech, Inc., Cipla, Inc. and Boehringer Ingelheim GmbH and etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Human Immunodeficiency Virus (HIV) Therapeutics companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Human Immunodeficiency Virus (HIV) Therapeutics Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Human Immunodeficiency Virus (HIV) Therapeutics Market Segment Percentages, by Type, 2021 (%)
- NRTIs
- NNRTIs
- Entry and Fusion Inhibitors
- Protease Inhibitors
- Integrase Inhibitors
- Coreceptor Antagonists
Global Human Immunodeficiency Virus (HIV) Therapeutics Market Segment Percentages, by Application, 2021 (%)
- Hospitals
- Clinics
- Labs
Global Human Immunodeficiency Virus (HIV) Therapeutics Market Segment Percentages, By Region and Country, 2021 (%)
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- France
- U.K.
- Italy
- Russia
- Nordic Countries
- Benelux
- Rest of Europe
- Asia
- China
- Japan
- South Korea
- Southeast Asia
- India
- Rest of Asia
- South America
- Brazil
- Argentina
- Rest of South America
- Middle East & Africa
- Turkey
- Israel
- Saudi Arabia
- UAE
- Rest of Middle East & Africa
The report also provides analysis of leading market participants including:
Key companies Human Immunodeficiency Virus (HIV) Therapeutics revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Human Immunodeficiency Virus (HIV) Therapeutics revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
- ViiV Healthcare
- Mylan
- AbbVie
- Merck & Co., Inc.
- Bristol-Myers Squibb Company
- Boehringer Ingelheim GmbH
- Genentech, Inc.
- Cipla, Inc.
- Boehringer Ingelheim GmbH
- Genentech, Inc.
1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS
1.1 Human Immunodeficiency Virus (HIV) Therapeutics Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Human Immunodeficiency Virus (HIV) Therapeutics Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 GLOBAL HUMAN IMMUNODEFICIENCY VIRUS (HIV) THERAPEUTICS OVERALL MARKET SIZE
2.1 Global Human Immunodeficiency Virus (HIV) Therapeutics Market Size: 2021 VS 2028
2.2 Global Human Immunodeficiency Virus (HIV) Therapeutics Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 COMPANY LANDSCAPE
3.1 Top Human Immunodeficiency Virus (HIV) Therapeutics Players in Global Market
3.2 Top Global Human Immunodeficiency Virus (HIV) Therapeutics Companies Ranked by Revenue
3.3 Global Human Immunodeficiency Virus (HIV) Therapeutics Revenue by Companies
3.4 Top 3 and Top 5 Human Immunodeficiency Virus (HIV) Therapeutics Companies in Global Market, by Revenue in 2021
3.5 Global Companies Human Immunodeficiency Virus (HIV) Therapeutics Product Type
3.6 Tier 1, Tier 2 and Tier 3 Human Immunodeficiency Virus (HIV) Therapeutics Players in Global Market
3.6.1 List of Global Tier 1 Human Immunodeficiency Virus (HIV) Therapeutics Companies
3.6.2 List of Global Tier 2 and Tier 3 Human Immunodeficiency Virus (HIV) Therapeutics Companies
4 MARKET SIGHTS BY PRODUCT
4.1 Overview
4.1.1 by Type - Global Human Immunodeficiency Virus (HIV) Therapeutics Market Size Markets, 2021 & 2028
4.1.2 NRTIs
4.1.3 NNRTIs
4.1.4 Entry and Fusion Inhibitors
4.1.5 Protease Inhibitors
4.1.6 Integrase Inhibitors
4.1.7 Coreceptor Antagonists
4.2 By Type - Global Human Immunodeficiency Virus (HIV) Therapeutics Revenue & Forecasts
4.2.1 By Type - Global Human Immunodeficiency Virus (HIV) Therapeutics Revenue, 2017-2022
4.2.2 By Type - Global Human Immunodeficiency Virus (HIV) Therapeutics Revenue, 2023-2028
4.2.3 By Type - Global Human Immunodeficiency Virus (HIV) Therapeutics Revenue Market Share, 2017-2028
5 SIGHTS BY APPLICATION
5.1 Overview
5.1.1 By Application - Global Human Immunodeficiency Virus (HIV) Therapeutics Market Size, 2021 & 2028
5.1.2 Hospitals
5.1.3 Clinics
5.1.4 Labs
5.2 By Application - Global Human Immunodeficiency Virus (HIV) Therapeutics Revenue & Forecasts
5.2.1 By Application - Global Human Immunodeficiency Virus (HIV) Therapeutics Revenue, 2017-2022
5.2.2 By Application - Global Human Immunodeficiency Virus (HIV) Therapeutics Revenue, 2023-2028
5.2.3 By Application - Global Human Immunodeficiency Virus (HIV) Therapeutics Revenue Market Share, 2017-2028
6 SIGHTS BY REGION
6.1 By Region - Global Human Immunodeficiency Virus (HIV) Therapeutics Market Size, 2021 & 2028
6.2 By Region - Global Human Immunodeficiency Virus (HIV) Therapeutics Revenue & Forecasts
6.2.1 By Region - Global Human Immunodeficiency Virus (HIV) Therapeutics Revenue, 2017-2022
6.2.2 By Region - Global Human Immunodeficiency Virus (HIV) Therapeutics Revenue, 2023-2028
6.2.3 By Region - Global Human Immunodeficiency Virus (HIV) Therapeutics Revenue Market Share, 2017-2028
6.3 North America
6.3.1 By Country - North America Human Immunodeficiency Virus (HIV) Therapeutics Revenue, 2017-2028
6.3.2 US Human Immunodeficiency Virus (HIV) Therapeutics Market Size, 2017-2028
6.3.3 Canada Human Immunodeficiency Virus (HIV) Therapeutics Market Size, 2017-2028
6.3.4 Mexico Human Immunodeficiency Virus (HIV) Therapeutics Market Size, 2017-2028
6.4 Europe
6.4.1 By Country - Europe Human Immunodeficiency Virus (HIV) Therapeutics Revenue, 2017-2028
6.4.2 Germany Human Immunodeficiency Virus (HIV) Therapeutics Market Size, 2017-2028
6.4.3 France Human Immunodeficiency Virus (HIV) Therapeutics Market Size, 2017-2028
6.4.4 U.K. Human Immunodeficiency Virus (HIV) Therapeutics Market Size, 2017-2028
6.4.5 Italy Human Immunodeficiency Virus (HIV) Therapeutics Market Size, 2017-2028
6.4.6 Russia Human Immunodeficiency Virus (HIV) Therapeutics Market Size, 2017-2028
6.4.7 Nordic Countries Human Immunodeficiency Virus (HIV) Therapeutics Market Size, 2017-2028
6.4.8 Benelux Human Immunodeficiency Virus (HIV) Therapeutics Market Size, 2017-2028
6.5 Asia
6.5.1 By Region - Asia Human Immunodeficiency Virus (HIV) Therapeutics Revenue, 2017-2028
6.5.2 China Human Immunodeficiency Virus (HIV) Therapeutics Market Size, 2017-2028
6.5.3 Japan Human Immunodeficiency Virus (HIV) Therapeutics Market Size, 2017-2028
6.5.4 South Korea Human Immunodeficiency Virus (HIV) Therapeutics Market Size, 2017-2028
6.5.5 Southeast Asia Human Immunodeficiency Virus (HIV) Therapeutics Market Size, 2017-2028
6.5.6 India Human Immunodeficiency Virus (HIV) Therapeutics Market Size, 2017-2028
6.6 South America
6.6.1 By Country - South America Human Immunodeficiency Virus (HIV) Therapeutics Revenue, 2017-2028
6.6.2 Brazil Human Immunodeficiency Virus (HIV) Therapeutics Market Size, 2017-2028
6.6.3 Argentina Human Immunodeficiency Virus (HIV) Therapeutics Market Size, 2017-2028
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Human Immunodeficiency Virus (HIV) Therapeutics Revenue, 2017-2028
6.7.2 Turkey Human Immunodeficiency Virus (HIV) Therapeutics Market Size, 2017-2028
6.7.3 Israel Human Immunodeficiency Virus (HIV) Therapeutics Market Size, 2017-2028
6.7.4 Saudi Arabia Human Immunodeficiency Virus (HIV) Therapeutics Market Size, 2017-2028
6.7.5 UAE Human Immunodeficiency Virus (HIV) Therapeutics Market Size, 2017-2028
7 PLAYERS PROFILES
7.1 ViiV Healthcare
7.1.1 ViiV Healthcare Corporate Summary
7.1.2 ViiV Healthcare Business Overview
7.1.3 ViiV Healthcare Human Immunodeficiency Virus (HIV) Therapeutics Major Product Offerings
7.1.4 ViiV Healthcare Human Immunodeficiency Virus (HIV) Therapeutics Revenue in Global Market (2017-2022)
7.1.5 ViiV Healthcare Key News
7.2 Mylan
7.2.1 Mylan Corporate Summary
7.2.2 Mylan Business Overview
7.2.3 Mylan Human Immunodeficiency Virus (HIV) Therapeutics Major Product Offerings
7.2.4 Mylan Human Immunodeficiency Virus (HIV) Therapeutics Revenue in Global Market (2017-2022)
7.2.5 Mylan Key News
7.3 AbbVie
7.3.1 AbbVie Corporate Summary
7.3.2 AbbVie Business Overview
7.3.3 AbbVie Human Immunodeficiency Virus (HIV) Therapeutics Major Product Offerings
7.3.4 AbbVie Human Immunodeficiency Virus (HIV) Therapeutics Revenue in Global Market (2017-2022)
7.3.5 AbbVie Key News
7.4 Merck & Co., Inc.
7.4.1 Merck & Co., Inc. Corporate Summary
7.4.2 Merck & Co., Inc. Business Overview
7.4.3 Merck & Co., Inc. Human Immunodeficiency Virus (HIV) Therapeutics Major Product Offerings
7.4.4 Merck & Co., Inc. Human Immunodeficiency Virus (HIV) Therapeutics Revenue in Global Market (2017-2022)
7.4.5 Merck & Co., Inc. Key News
7.5 Bristol-Myers Squibb Company
7.5.1 Bristol-Myers Squibb Company Corporate Summary
7.5.2 Bristol-Myers Squibb Company Business Overview
7.5.3 Bristol-Myers Squibb Company Human Immunodeficiency Virus (HIV) Therapeutics Major Product Offerings
7.5.4 Bristol-Myers Squibb Company Human Immunodeficiency Virus (HIV) Therapeutics Revenue in Global Market (2017-2022)
7.5.5 Bristol-Myers Squibb Company Key News
7.6 Boehringer Ingelheim GmbH
7.6.1 Boehringer Ingelheim GmbH Corporate Summary
7.6.2 Boehringer Ingelheim GmbH Business Overview
7.6.3 Boehringer Ingelheim GmbH Human Immunodeficiency Virus (HIV) Therapeutics Major Product Offerings
7.6.4 Boehringer Ingelheim GmbH Human Immunodeficiency Virus (HIV) Therapeutics Revenue in Global Market (2017-2022)
7.6.5 Boehringer Ingelheim GmbH Key News
7.7 Genentech, Inc.
7.7.1 Genentech, Inc. Corporate Summary
7.7.2 Genentech, Inc. Business Overview
7.7.3 Genentech, Inc. Human Immunodeficiency Virus (HIV) Therapeutics Major Product Offerings
7.7.4 Genentech, Inc. Human Immunodeficiency Virus (HIV) Therapeutics Revenue in Global Market (2017-2022)
7.7.5 Genentech, Inc. Key News
7.8 Cipla, Inc.
7.8.1 Cipla, Inc. Corporate Summary
7.8.2 Cipla, Inc. Business Overview
7.8.3 Cipla, Inc. Human Immunodeficiency Virus (HIV) Therapeutics Major Product Offerings
7.8.4 Cipla, Inc. Human Immunodeficiency Virus (HIV) Therapeutics Revenue in Global Market (2017-2022)
7.8.5 Cipla, Inc. Key News
7.9 Boehringer Ingelheim GmbH
7.9.1 Boehringer Ingelheim GmbH Corporate Summary
7.9.2 Boehringer Ingelheim GmbH Business Overview
7.9.3 Boehringer Ingelheim GmbH Human Immunodeficiency Virus (HIV) Therapeutics Major Product Offerings
7.9.4 Boehringer Ingelheim GmbH Human Immunodeficiency Virus (HIV) Therapeutics Revenue in Global Market (2017-2022)
7.9.5 Boehringer Ingelheim GmbH Key News
7.10 Genentech, Inc.
7.10.1 Genentech, Inc. Corporate Summary
7.10.2 Genentech, Inc. Business Overview
7.10.3 Genentech, Inc. Human Immunodeficiency Virus (HIV) Therapeutics Major Product Offerings
7.10.4 Genentech, Inc. Human Immunodeficiency Virus (HIV) Therapeutics Revenue in Global Market (2017-2022)
7.10.5 Genentech, Inc. Key News
8 CONCLUSION
9 APPENDIX
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
1.1 Human Immunodeficiency Virus (HIV) Therapeutics Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Human Immunodeficiency Virus (HIV) Therapeutics Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 GLOBAL HUMAN IMMUNODEFICIENCY VIRUS (HIV) THERAPEUTICS OVERALL MARKET SIZE
2.1 Global Human Immunodeficiency Virus (HIV) Therapeutics Market Size: 2021 VS 2028
2.2 Global Human Immunodeficiency Virus (HIV) Therapeutics Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 COMPANY LANDSCAPE
3.1 Top Human Immunodeficiency Virus (HIV) Therapeutics Players in Global Market
3.2 Top Global Human Immunodeficiency Virus (HIV) Therapeutics Companies Ranked by Revenue
3.3 Global Human Immunodeficiency Virus (HIV) Therapeutics Revenue by Companies
3.4 Top 3 and Top 5 Human Immunodeficiency Virus (HIV) Therapeutics Companies in Global Market, by Revenue in 2021
3.5 Global Companies Human Immunodeficiency Virus (HIV) Therapeutics Product Type
3.6 Tier 1, Tier 2 and Tier 3 Human Immunodeficiency Virus (HIV) Therapeutics Players in Global Market
3.6.1 List of Global Tier 1 Human Immunodeficiency Virus (HIV) Therapeutics Companies
3.6.2 List of Global Tier 2 and Tier 3 Human Immunodeficiency Virus (HIV) Therapeutics Companies
4 MARKET SIGHTS BY PRODUCT
4.1 Overview
4.1.1 by Type - Global Human Immunodeficiency Virus (HIV) Therapeutics Market Size Markets, 2021 & 2028
4.1.2 NRTIs
4.1.3 NNRTIs
4.1.4 Entry and Fusion Inhibitors
4.1.5 Protease Inhibitors
4.1.6 Integrase Inhibitors
4.1.7 Coreceptor Antagonists
4.2 By Type - Global Human Immunodeficiency Virus (HIV) Therapeutics Revenue & Forecasts
4.2.1 By Type - Global Human Immunodeficiency Virus (HIV) Therapeutics Revenue, 2017-2022
4.2.2 By Type - Global Human Immunodeficiency Virus (HIV) Therapeutics Revenue, 2023-2028
4.2.3 By Type - Global Human Immunodeficiency Virus (HIV) Therapeutics Revenue Market Share, 2017-2028
5 SIGHTS BY APPLICATION
5.1 Overview
5.1.1 By Application - Global Human Immunodeficiency Virus (HIV) Therapeutics Market Size, 2021 & 2028
5.1.2 Hospitals
5.1.3 Clinics
5.1.4 Labs
5.2 By Application - Global Human Immunodeficiency Virus (HIV) Therapeutics Revenue & Forecasts
5.2.1 By Application - Global Human Immunodeficiency Virus (HIV) Therapeutics Revenue, 2017-2022
5.2.2 By Application - Global Human Immunodeficiency Virus (HIV) Therapeutics Revenue, 2023-2028
5.2.3 By Application - Global Human Immunodeficiency Virus (HIV) Therapeutics Revenue Market Share, 2017-2028
6 SIGHTS BY REGION
6.1 By Region - Global Human Immunodeficiency Virus (HIV) Therapeutics Market Size, 2021 & 2028
6.2 By Region - Global Human Immunodeficiency Virus (HIV) Therapeutics Revenue & Forecasts
6.2.1 By Region - Global Human Immunodeficiency Virus (HIV) Therapeutics Revenue, 2017-2022
6.2.2 By Region - Global Human Immunodeficiency Virus (HIV) Therapeutics Revenue, 2023-2028
6.2.3 By Region - Global Human Immunodeficiency Virus (HIV) Therapeutics Revenue Market Share, 2017-2028
6.3 North America
6.3.1 By Country - North America Human Immunodeficiency Virus (HIV) Therapeutics Revenue, 2017-2028
6.3.2 US Human Immunodeficiency Virus (HIV) Therapeutics Market Size, 2017-2028
6.3.3 Canada Human Immunodeficiency Virus (HIV) Therapeutics Market Size, 2017-2028
6.3.4 Mexico Human Immunodeficiency Virus (HIV) Therapeutics Market Size, 2017-2028
6.4 Europe
6.4.1 By Country - Europe Human Immunodeficiency Virus (HIV) Therapeutics Revenue, 2017-2028
6.4.2 Germany Human Immunodeficiency Virus (HIV) Therapeutics Market Size, 2017-2028
6.4.3 France Human Immunodeficiency Virus (HIV) Therapeutics Market Size, 2017-2028
6.4.4 U.K. Human Immunodeficiency Virus (HIV) Therapeutics Market Size, 2017-2028
6.4.5 Italy Human Immunodeficiency Virus (HIV) Therapeutics Market Size, 2017-2028
6.4.6 Russia Human Immunodeficiency Virus (HIV) Therapeutics Market Size, 2017-2028
6.4.7 Nordic Countries Human Immunodeficiency Virus (HIV) Therapeutics Market Size, 2017-2028
6.4.8 Benelux Human Immunodeficiency Virus (HIV) Therapeutics Market Size, 2017-2028
6.5 Asia
6.5.1 By Region - Asia Human Immunodeficiency Virus (HIV) Therapeutics Revenue, 2017-2028
6.5.2 China Human Immunodeficiency Virus (HIV) Therapeutics Market Size, 2017-2028
6.5.3 Japan Human Immunodeficiency Virus (HIV) Therapeutics Market Size, 2017-2028
6.5.4 South Korea Human Immunodeficiency Virus (HIV) Therapeutics Market Size, 2017-2028
6.5.5 Southeast Asia Human Immunodeficiency Virus (HIV) Therapeutics Market Size, 2017-2028
6.5.6 India Human Immunodeficiency Virus (HIV) Therapeutics Market Size, 2017-2028
6.6 South America
6.6.1 By Country - South America Human Immunodeficiency Virus (HIV) Therapeutics Revenue, 2017-2028
6.6.2 Brazil Human Immunodeficiency Virus (HIV) Therapeutics Market Size, 2017-2028
6.6.3 Argentina Human Immunodeficiency Virus (HIV) Therapeutics Market Size, 2017-2028
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Human Immunodeficiency Virus (HIV) Therapeutics Revenue, 2017-2028
6.7.2 Turkey Human Immunodeficiency Virus (HIV) Therapeutics Market Size, 2017-2028
6.7.3 Israel Human Immunodeficiency Virus (HIV) Therapeutics Market Size, 2017-2028
6.7.4 Saudi Arabia Human Immunodeficiency Virus (HIV) Therapeutics Market Size, 2017-2028
6.7.5 UAE Human Immunodeficiency Virus (HIV) Therapeutics Market Size, 2017-2028
7 PLAYERS PROFILES
7.1 ViiV Healthcare
7.1.1 ViiV Healthcare Corporate Summary
7.1.2 ViiV Healthcare Business Overview
7.1.3 ViiV Healthcare Human Immunodeficiency Virus (HIV) Therapeutics Major Product Offerings
7.1.4 ViiV Healthcare Human Immunodeficiency Virus (HIV) Therapeutics Revenue in Global Market (2017-2022)
7.1.5 ViiV Healthcare Key News
7.2 Mylan
7.2.1 Mylan Corporate Summary
7.2.2 Mylan Business Overview
7.2.3 Mylan Human Immunodeficiency Virus (HIV) Therapeutics Major Product Offerings
7.2.4 Mylan Human Immunodeficiency Virus (HIV) Therapeutics Revenue in Global Market (2017-2022)
7.2.5 Mylan Key News
7.3 AbbVie
7.3.1 AbbVie Corporate Summary
7.3.2 AbbVie Business Overview
7.3.3 AbbVie Human Immunodeficiency Virus (HIV) Therapeutics Major Product Offerings
7.3.4 AbbVie Human Immunodeficiency Virus (HIV) Therapeutics Revenue in Global Market (2017-2022)
7.3.5 AbbVie Key News
7.4 Merck & Co., Inc.
7.4.1 Merck & Co., Inc. Corporate Summary
7.4.2 Merck & Co., Inc. Business Overview
7.4.3 Merck & Co., Inc. Human Immunodeficiency Virus (HIV) Therapeutics Major Product Offerings
7.4.4 Merck & Co., Inc. Human Immunodeficiency Virus (HIV) Therapeutics Revenue in Global Market (2017-2022)
7.4.5 Merck & Co., Inc. Key News
7.5 Bristol-Myers Squibb Company
7.5.1 Bristol-Myers Squibb Company Corporate Summary
7.5.2 Bristol-Myers Squibb Company Business Overview
7.5.3 Bristol-Myers Squibb Company Human Immunodeficiency Virus (HIV) Therapeutics Major Product Offerings
7.5.4 Bristol-Myers Squibb Company Human Immunodeficiency Virus (HIV) Therapeutics Revenue in Global Market (2017-2022)
7.5.5 Bristol-Myers Squibb Company Key News
7.6 Boehringer Ingelheim GmbH
7.6.1 Boehringer Ingelheim GmbH Corporate Summary
7.6.2 Boehringer Ingelheim GmbH Business Overview
7.6.3 Boehringer Ingelheim GmbH Human Immunodeficiency Virus (HIV) Therapeutics Major Product Offerings
7.6.4 Boehringer Ingelheim GmbH Human Immunodeficiency Virus (HIV) Therapeutics Revenue in Global Market (2017-2022)
7.6.5 Boehringer Ingelheim GmbH Key News
7.7 Genentech, Inc.
7.7.1 Genentech, Inc. Corporate Summary
7.7.2 Genentech, Inc. Business Overview
7.7.3 Genentech, Inc. Human Immunodeficiency Virus (HIV) Therapeutics Major Product Offerings
7.7.4 Genentech, Inc. Human Immunodeficiency Virus (HIV) Therapeutics Revenue in Global Market (2017-2022)
7.7.5 Genentech, Inc. Key News
7.8 Cipla, Inc.
7.8.1 Cipla, Inc. Corporate Summary
7.8.2 Cipla, Inc. Business Overview
7.8.3 Cipla, Inc. Human Immunodeficiency Virus (HIV) Therapeutics Major Product Offerings
7.8.4 Cipla, Inc. Human Immunodeficiency Virus (HIV) Therapeutics Revenue in Global Market (2017-2022)
7.8.5 Cipla, Inc. Key News
7.9 Boehringer Ingelheim GmbH
7.9.1 Boehringer Ingelheim GmbH Corporate Summary
7.9.2 Boehringer Ingelheim GmbH Business Overview
7.9.3 Boehringer Ingelheim GmbH Human Immunodeficiency Virus (HIV) Therapeutics Major Product Offerings
7.9.4 Boehringer Ingelheim GmbH Human Immunodeficiency Virus (HIV) Therapeutics Revenue in Global Market (2017-2022)
7.9.5 Boehringer Ingelheim GmbH Key News
7.10 Genentech, Inc.
7.10.1 Genentech, Inc. Corporate Summary
7.10.2 Genentech, Inc. Business Overview
7.10.3 Genentech, Inc. Human Immunodeficiency Virus (HIV) Therapeutics Major Product Offerings
7.10.4 Genentech, Inc. Human Immunodeficiency Virus (HIV) Therapeutics Revenue in Global Market (2017-2022)
7.10.5 Genentech, Inc. Key News
8 CONCLUSION
9 APPENDIX
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES
Table 1. Human Immunodeficiency Virus (HIV) Therapeutics Market Opportunities & Trends in Global Market
Table 2. Human Immunodeficiency Virus (HIV) Therapeutics Market Drivers in Global Market
Table 3. Human Immunodeficiency Virus (HIV) Therapeutics Market Restraints in Global Market
Table 4. Key Players of Human Immunodeficiency Virus (HIV) Therapeutics in Global Market
Table 5. Top Human Immunodeficiency Virus (HIV) Therapeutics Players in Global Market, Ranking by Revenue (2021)
Table 6. Global Human Immunodeficiency Virus (HIV) Therapeutics Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global Human Immunodeficiency Virus (HIV) Therapeutics Revenue Share by Companies, 2017-2022
Table 8. Global Companies Human Immunodeficiency Virus (HIV) Therapeutics Product Type
Table 9. List of Global Tier 1 Human Immunodeficiency Virus (HIV) Therapeutics Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Human Immunodeficiency Virus (HIV) Therapeutics Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type – Global Human Immunodeficiency Virus (HIV) Therapeutics Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Human Immunodeficiency Virus (HIV) Therapeutics Revenue in Global (US$, Mn), 2017-2022
Table 13. By Type - Human Immunodeficiency Virus (HIV) Therapeutics Revenue in Global (US$, Mn), 2023-2028
Table 14. By Application – Global Human Immunodeficiency Virus (HIV) Therapeutics Revenue, (US$, Mn), 2021 & 2028
Table 15. By Application - Human Immunodeficiency Virus (HIV) Therapeutics Revenue in Global (US$, Mn), 2017-2022
Table 16. By Application - Human Immunodeficiency Virus (HIV) Therapeutics Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region – Global Human Immunodeficiency Virus (HIV) Therapeutics Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global Human Immunodeficiency Virus (HIV) Therapeutics Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global Human Immunodeficiency Virus (HIV) Therapeutics Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America Human Immunodeficiency Virus (HIV) Therapeutics Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America Human Immunodeficiency Virus (HIV) Therapeutics Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe Human Immunodeficiency Virus (HIV) Therapeutics Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe Human Immunodeficiency Virus (HIV) Therapeutics Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia Human Immunodeficiency Virus (HIV) Therapeutics Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia Human Immunodeficiency Virus (HIV) Therapeutics Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America Human Immunodeficiency Virus (HIV) Therapeutics Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America Human Immunodeficiency Virus (HIV) Therapeutics Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa Human Immunodeficiency Virus (HIV) Therapeutics Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa Human Immunodeficiency Virus (HIV) Therapeutics Revenue, (US$, Mn), 2023-2028
Table 30. ViiV Healthcare Corporate Summary
Table 31. ViiV Healthcare Human Immunodeficiency Virus (HIV) Therapeutics Product Offerings
Table 32. ViiV Healthcare Human Immunodeficiency Virus (HIV) Therapeutics Revenue (US$, Mn), (2017-2022)
Table 33. Mylan Corporate Summary
Table 34. Mylan Human Immunodeficiency Virus (HIV) Therapeutics Product Offerings
Table 35. Mylan Human Immunodeficiency Virus (HIV) Therapeutics Revenue (US$, Mn), (2017-2022)
Table 36. AbbVie Corporate Summary
Table 37. AbbVie Human Immunodeficiency Virus (HIV) Therapeutics Product Offerings
Table 38. AbbVie Human Immunodeficiency Virus (HIV) Therapeutics Revenue (US$, Mn), (2017-2022)
Table 39. Merck & Co., Inc. Corporate Summary
Table 40. Merck & Co., Inc. Human Immunodeficiency Virus (HIV) Therapeutics Product Offerings
Table 41. Merck & Co., Inc. Human Immunodeficiency Virus (HIV) Therapeutics Revenue (US$, Mn), (2017-2022)
Table 42. Bristol-Myers Squibb Company Corporate Summary
Table 43. Bristol-Myers Squibb Company Human Immunodeficiency Virus (HIV) Therapeutics Product Offerings
Table 44. Bristol-Myers Squibb Company Human Immunodeficiency Virus (HIV) Therapeutics Revenue (US$, Mn), (2017-2022)
Table 45. Boehringer Ingelheim GmbH Corporate Summary
Table 46. Boehringer Ingelheim GmbH Human Immunodeficiency Virus (HIV) Therapeutics Product Offerings
Table 47. Boehringer Ingelheim GmbH Human Immunodeficiency Virus (HIV) Therapeutics Revenue (US$, Mn), (2017-2022)
Table 48. Genentech, Inc. Corporate Summary
Table 49. Genentech, Inc. Human Immunodeficiency Virus (HIV) Therapeutics Product Offerings
Table 50. Genentech, Inc. Human Immunodeficiency Virus (HIV) Therapeutics Revenue (US$, Mn), (2017-2022)
Table 51. Cipla, Inc. Corporate Summary
Table 52. Cipla, Inc. Human Immunodeficiency Virus (HIV) Therapeutics Product Offerings
Table 53. Cipla, Inc. Human Immunodeficiency Virus (HIV) Therapeutics Revenue (US$, Mn), (2017-2022)
Table 54. Boehringer Ingelheim GmbH Corporate Summary
Table 55. Boehringer Ingelheim GmbH Human Immunodeficiency Virus (HIV) Therapeutics Product Offerings
Table 56. Boehringer Ingelheim GmbH Human Immunodeficiency Virus (HIV) Therapeutics Revenue (US$, Mn), (2017-2022)
Table 57. Genentech, Inc. Corporate Summary
Table 58. Genentech, Inc. Human Immunodeficiency Virus (HIV) Therapeutics Product Offerings
Table 59. Genentech, Inc. Human Immunodeficiency Virus (HIV) Therapeutics Revenue (US$, Mn), (2017-2022)
Table 1. Human Immunodeficiency Virus (HIV) Therapeutics Market Opportunities & Trends in Global Market
Table 2. Human Immunodeficiency Virus (HIV) Therapeutics Market Drivers in Global Market
Table 3. Human Immunodeficiency Virus (HIV) Therapeutics Market Restraints in Global Market
Table 4. Key Players of Human Immunodeficiency Virus (HIV) Therapeutics in Global Market
Table 5. Top Human Immunodeficiency Virus (HIV) Therapeutics Players in Global Market, Ranking by Revenue (2021)
Table 6. Global Human Immunodeficiency Virus (HIV) Therapeutics Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global Human Immunodeficiency Virus (HIV) Therapeutics Revenue Share by Companies, 2017-2022
Table 8. Global Companies Human Immunodeficiency Virus (HIV) Therapeutics Product Type
Table 9. List of Global Tier 1 Human Immunodeficiency Virus (HIV) Therapeutics Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Human Immunodeficiency Virus (HIV) Therapeutics Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type – Global Human Immunodeficiency Virus (HIV) Therapeutics Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Human Immunodeficiency Virus (HIV) Therapeutics Revenue in Global (US$, Mn), 2017-2022
Table 13. By Type - Human Immunodeficiency Virus (HIV) Therapeutics Revenue in Global (US$, Mn), 2023-2028
Table 14. By Application – Global Human Immunodeficiency Virus (HIV) Therapeutics Revenue, (US$, Mn), 2021 & 2028
Table 15. By Application - Human Immunodeficiency Virus (HIV) Therapeutics Revenue in Global (US$, Mn), 2017-2022
Table 16. By Application - Human Immunodeficiency Virus (HIV) Therapeutics Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region – Global Human Immunodeficiency Virus (HIV) Therapeutics Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global Human Immunodeficiency Virus (HIV) Therapeutics Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global Human Immunodeficiency Virus (HIV) Therapeutics Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America Human Immunodeficiency Virus (HIV) Therapeutics Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America Human Immunodeficiency Virus (HIV) Therapeutics Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe Human Immunodeficiency Virus (HIV) Therapeutics Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe Human Immunodeficiency Virus (HIV) Therapeutics Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia Human Immunodeficiency Virus (HIV) Therapeutics Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia Human Immunodeficiency Virus (HIV) Therapeutics Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America Human Immunodeficiency Virus (HIV) Therapeutics Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America Human Immunodeficiency Virus (HIV) Therapeutics Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa Human Immunodeficiency Virus (HIV) Therapeutics Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa Human Immunodeficiency Virus (HIV) Therapeutics Revenue, (US$, Mn), 2023-2028
Table 30. ViiV Healthcare Corporate Summary
Table 31. ViiV Healthcare Human Immunodeficiency Virus (HIV) Therapeutics Product Offerings
Table 32. ViiV Healthcare Human Immunodeficiency Virus (HIV) Therapeutics Revenue (US$, Mn), (2017-2022)
Table 33. Mylan Corporate Summary
Table 34. Mylan Human Immunodeficiency Virus (HIV) Therapeutics Product Offerings
Table 35. Mylan Human Immunodeficiency Virus (HIV) Therapeutics Revenue (US$, Mn), (2017-2022)
Table 36. AbbVie Corporate Summary
Table 37. AbbVie Human Immunodeficiency Virus (HIV) Therapeutics Product Offerings
Table 38. AbbVie Human Immunodeficiency Virus (HIV) Therapeutics Revenue (US$, Mn), (2017-2022)
Table 39. Merck & Co., Inc. Corporate Summary
Table 40. Merck & Co., Inc. Human Immunodeficiency Virus (HIV) Therapeutics Product Offerings
Table 41. Merck & Co., Inc. Human Immunodeficiency Virus (HIV) Therapeutics Revenue (US$, Mn), (2017-2022)
Table 42. Bristol-Myers Squibb Company Corporate Summary
Table 43. Bristol-Myers Squibb Company Human Immunodeficiency Virus (HIV) Therapeutics Product Offerings
Table 44. Bristol-Myers Squibb Company Human Immunodeficiency Virus (HIV) Therapeutics Revenue (US$, Mn), (2017-2022)
Table 45. Boehringer Ingelheim GmbH Corporate Summary
Table 46. Boehringer Ingelheim GmbH Human Immunodeficiency Virus (HIV) Therapeutics Product Offerings
Table 47. Boehringer Ingelheim GmbH Human Immunodeficiency Virus (HIV) Therapeutics Revenue (US$, Mn), (2017-2022)
Table 48. Genentech, Inc. Corporate Summary
Table 49. Genentech, Inc. Human Immunodeficiency Virus (HIV) Therapeutics Product Offerings
Table 50. Genentech, Inc. Human Immunodeficiency Virus (HIV) Therapeutics Revenue (US$, Mn), (2017-2022)
Table 51. Cipla, Inc. Corporate Summary
Table 52. Cipla, Inc. Human Immunodeficiency Virus (HIV) Therapeutics Product Offerings
Table 53. Cipla, Inc. Human Immunodeficiency Virus (HIV) Therapeutics Revenue (US$, Mn), (2017-2022)
Table 54. Boehringer Ingelheim GmbH Corporate Summary
Table 55. Boehringer Ingelheim GmbH Human Immunodeficiency Virus (HIV) Therapeutics Product Offerings
Table 56. Boehringer Ingelheim GmbH Human Immunodeficiency Virus (HIV) Therapeutics Revenue (US$, Mn), (2017-2022)
Table 57. Genentech, Inc. Corporate Summary
Table 58. Genentech, Inc. Human Immunodeficiency Virus (HIV) Therapeutics Product Offerings
Table 59. Genentech, Inc. Human Immunodeficiency Virus (HIV) Therapeutics Revenue (US$, Mn), (2017-2022)
LIST OF FIGURES
Figure 1. Human Immunodeficiency Virus (HIV) Therapeutics Segment by Type in 2021
Figure 2. Human Immunodeficiency Virus (HIV) Therapeutics Segment by Application in 2021
Figure 3. Global Human Immunodeficiency Virus (HIV) Therapeutics Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Human Immunodeficiency Virus (HIV) Therapeutics Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Human Immunodeficiency Virus (HIV) Therapeutics Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Human Immunodeficiency Virus (HIV) Therapeutics Revenue in 2021
Figure 8. By Type - Global Human Immunodeficiency Virus (HIV) Therapeutics Revenue Market Share, 2017-2028
Figure 9. By Application - Global Human Immunodeficiency Virus (HIV) Therapeutics Revenue Market Share, 2017-2028
Figure 10. By Region - Global Human Immunodeficiency Virus (HIV) Therapeutics Revenue Market Share, 2017-2028
Figure 11. By Country - North America Human Immunodeficiency Virus (HIV) Therapeutics Revenue Market Share, 2017-2028
Figure 12. US Human Immunodeficiency Virus (HIV) Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 13. Canada Human Immunodeficiency Virus (HIV) Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico Human Immunodeficiency Virus (HIV) Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe Human Immunodeficiency Virus (HIV) Therapeutics Revenue Market Share, 2017-2028
Figure 16. Germany Human Immunodeficiency Virus (HIV) Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 17. France Human Immunodeficiency Virus (HIV) Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. Human Immunodeficiency Virus (HIV) Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 19. Italy Human Immunodeficiency Virus (HIV) Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 20. Russia Human Immunodeficiency Virus (HIV) Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries Human Immunodeficiency Virus (HIV) Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux Human Immunodeficiency Virus (HIV) Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia Human Immunodeficiency Virus (HIV) Therapeutics Revenue Market Share, 2017-2028
Figure 24. China Human Immunodeficiency Virus (HIV) Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 25. Japan Human Immunodeficiency Virus (HIV) Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea Human Immunodeficiency Virus (HIV) Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia Human Immunodeficiency Virus (HIV) Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 28. India Human Immunodeficiency Virus (HIV) Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America Human Immunodeficiency Virus (HIV) Therapeutics Revenue Market Share, 2017-2028
Figure 30. Brazil Human Immunodeficiency Virus (HIV) Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina Human Immunodeficiency Virus (HIV) Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa Human Immunodeficiency Virus (HIV) Therapeutics Revenue Market Share, 2017-2028
Figure 33. Turkey Human Immunodeficiency Virus (HIV) Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 34. Israel Human Immunodeficiency Virus (HIV) Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia Human Immunodeficiency Virus (HIV) Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 36. UAE Human Immunodeficiency Virus (HIV) Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 37. ViiV Healthcare Human Immunodeficiency Virus (HIV) Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. Mylan Human Immunodeficiency Virus (HIV) Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. AbbVie Human Immunodeficiency Virus (HIV) Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. Merck & Co., Inc. Human Immunodeficiency Virus (HIV) Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 41. Bristol-Myers Squibb Company Human Immunodeficiency Virus (HIV) Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 42. Boehringer Ingelheim GmbH Human Immunodeficiency Virus (HIV) Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 43. Genentech, Inc. Human Immunodeficiency Virus (HIV) Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 44. Cipla, Inc. Human Immunodeficiency Virus (HIV) Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 45. Boehringer Ingelheim GmbH Human Immunodeficiency Virus (HIV) Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 46. Genentech, Inc. Human Immunodeficiency Virus (HIV) Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 1. Human Immunodeficiency Virus (HIV) Therapeutics Segment by Type in 2021
Figure 2. Human Immunodeficiency Virus (HIV) Therapeutics Segment by Application in 2021
Figure 3. Global Human Immunodeficiency Virus (HIV) Therapeutics Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Human Immunodeficiency Virus (HIV) Therapeutics Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Human Immunodeficiency Virus (HIV) Therapeutics Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Human Immunodeficiency Virus (HIV) Therapeutics Revenue in 2021
Figure 8. By Type - Global Human Immunodeficiency Virus (HIV) Therapeutics Revenue Market Share, 2017-2028
Figure 9. By Application - Global Human Immunodeficiency Virus (HIV) Therapeutics Revenue Market Share, 2017-2028
Figure 10. By Region - Global Human Immunodeficiency Virus (HIV) Therapeutics Revenue Market Share, 2017-2028
Figure 11. By Country - North America Human Immunodeficiency Virus (HIV) Therapeutics Revenue Market Share, 2017-2028
Figure 12. US Human Immunodeficiency Virus (HIV) Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 13. Canada Human Immunodeficiency Virus (HIV) Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico Human Immunodeficiency Virus (HIV) Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe Human Immunodeficiency Virus (HIV) Therapeutics Revenue Market Share, 2017-2028
Figure 16. Germany Human Immunodeficiency Virus (HIV) Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 17. France Human Immunodeficiency Virus (HIV) Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. Human Immunodeficiency Virus (HIV) Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 19. Italy Human Immunodeficiency Virus (HIV) Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 20. Russia Human Immunodeficiency Virus (HIV) Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries Human Immunodeficiency Virus (HIV) Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux Human Immunodeficiency Virus (HIV) Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia Human Immunodeficiency Virus (HIV) Therapeutics Revenue Market Share, 2017-2028
Figure 24. China Human Immunodeficiency Virus (HIV) Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 25. Japan Human Immunodeficiency Virus (HIV) Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea Human Immunodeficiency Virus (HIV) Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia Human Immunodeficiency Virus (HIV) Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 28. India Human Immunodeficiency Virus (HIV) Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America Human Immunodeficiency Virus (HIV) Therapeutics Revenue Market Share, 2017-2028
Figure 30. Brazil Human Immunodeficiency Virus (HIV) Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina Human Immunodeficiency Virus (HIV) Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa Human Immunodeficiency Virus (HIV) Therapeutics Revenue Market Share, 2017-2028
Figure 33. Turkey Human Immunodeficiency Virus (HIV) Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 34. Israel Human Immunodeficiency Virus (HIV) Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia Human Immunodeficiency Virus (HIV) Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 36. UAE Human Immunodeficiency Virus (HIV) Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 37. ViiV Healthcare Human Immunodeficiency Virus (HIV) Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. Mylan Human Immunodeficiency Virus (HIV) Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. AbbVie Human Immunodeficiency Virus (HIV) Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. Merck & Co., Inc. Human Immunodeficiency Virus (HIV) Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 41. Bristol-Myers Squibb Company Human Immunodeficiency Virus (HIV) Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 42. Boehringer Ingelheim GmbH Human Immunodeficiency Virus (HIV) Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 43. Genentech, Inc. Human Immunodeficiency Virus (HIV) Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 44. Cipla, Inc. Human Immunodeficiency Virus (HIV) Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 45. Boehringer Ingelheim GmbH Human Immunodeficiency Virus (HIV) Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 46. Genentech, Inc. Human Immunodeficiency Virus (HIV) Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
